NDAORALTABLET
Approved
Aug 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
TRIAVIL 2-25 (amitriptyline hydrochloride; perphenazine) by PharmaIN is clinical pharmacology amitriptyline hydrochloride is an antidepressant with sedative effects. Approved for depression. First approved in 1965.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIAVIL 2-25 is an oral fixed-dose combination tablet containing amitriptyline hydrochloride (a tricyclic antidepressant) and perphenazine (an antipsychotic) for the treatment of depression. Amitriptyline works by inhibiting the reuptake of norepinephrine and serotonin in adrenergic and serotonergic neurons, potentiating neuronal activity and producing antidepressant and sedative effects.
LOE Approaching
Product is in late maturity with LOE approaching; commercial team is likely focused on defend-and-harvest strategies rather than expansion, signaling smaller team size and stable headcount.
Mechanism of Action
CLINICAL PHARMACOLOGY Amitriptyline hydrochloride is an antidepressant with sedative effects. Its mechanism of action in man is not known. It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system. Amitriptyline inhibits the membrane pump…
Indications (1)
Career Relevance
Worked on TRIAVIL 2-25 at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.